Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$20.16
0.231.15%
At close: Jan 16, 4:00 PM EST
$20.22
0.060.30%
After Hours: Jan 16, 4:24 PM EST
Comments
Loading...
Zenas BioPharma Analyst Ratings and Price Targets | NASDAQ:ZBIO | Benzinga
Zenas BioPharma Inc has a consensus price target of $38 based on the ratings of 9 analysts. The high is $55 issued by Evercore ISI Group on November 26, 2025. The low is $19 issued by Morgan Stanley on January 6, 2026. The 3 most-recent analyst ratings were released by Morgan Stanley, Wedbush, and Evercore ISI Group on January 6, 2026, December 22, 2025, and November 26, 2025, respectively. With an average price target of $39.67 between Morgan Stanley, Wedbush, and Evercore ISI Group, there's an implied 96.18% upside for Zenas BioPharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
Wedbush
Evercore ISI Group
Citigroup
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Zenas BioPharma
FAQ
What is the target price for Zenas BioPharma (ZBIO) stock?
The latest price target for Zenas BioPharma (NASDAQ:ZBIO) was reported by Morgan Stanley on January 6, 2026. The analyst firm set a price target for $19.00 expecting ZBIO to fall to within 12 months (a possible -6.03% downside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Zenas BioPharma (ZBIO)?
The latest analyst rating for Zenas BioPharma (NASDAQ:ZBIO) was provided by Morgan Stanley, and Zenas BioPharma downgraded their equal-weight rating.
When was the last upgrade for Zenas BioPharma (ZBIO)?
There is no last upgrade for Zenas BioPharma
When was the last downgrade for Zenas BioPharma (ZBIO)?
The last downgrade for Zenas BioPharma Inc happened on January 6, 2026 when Morgan Stanley changed their price target from $37 to $19 for Zenas BioPharma Inc.
When is the next analyst rating going to be posted or updated for Zenas BioPharma (ZBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zenas BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zenas BioPharma was filed on January 6, 2026 so you should expect the next rating to be made available sometime around January 6, 2027.
Is the Analyst Rating Zenas BioPharma (ZBIO) correct?
While ratings are subjective and will change, the latest Zenas BioPharma (ZBIO) rating was a downgraded with a price target of $37.00 to $19.00. The current price Zenas BioPharma (ZBIO) is trading at is $20.22, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
